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Abstract
Background: Concomitant pulmonary and hepatic toxicity secondary to nitrofurantoin is a rare
but serious complication of the use of Nitrofurantoin.
Case presentation: A 72 year old woman taking Nitrofurantoin for recurrent urinary sepsis
presenting with breathlessness abdominal discomfort and abnormal liver function tests is described.
Drug toxicity secondary to Nitrofurantoin was diagnosed. Cessation of the drug and a course of
steroids markedly improved her condition.
Discussion:  We review the drug reactions associated with Nitrofurantoin and suggest an
alternative treatment strategy for recurrent urinary sepsis.
Conclusion: Adverse drug reactions are an important cause of concomitant lung and liver toxicity
and the mainstay of treatment is drug withdrawal.
Background
Nitrofurantoin is well recognized as a cause of adverse
drug reactions although the combination of lung and liver
toxicity is rare [1]. A case of concomitant lung and liver
toxicity in a patient taking nitrofurantoin and our
approach to management is described. We discuss the
presentation of nitrofurantoin induced drug reactions and
suggest an alternative treatment strategy for patients tak-
ing this drug for recurrent urinary tract infections.
Case presentation
A 72 year old retired woman presented to her General
Practitioner with breathlessness, upper abdominal dis-
comfort and nausea. She was treated initially for a lower
respiratory tract infection with a five day course of amox-
icillin and prednisone. Blood analysis at this time
revealed abnormal liver function tests (LFTs) [see addi-
tional file 1]. Her breathlessness continued to worsen after
this initial course of therapy and she was admitted for fur-
ther investigation and treatment.
A review of her history in the months prior to this acute
deterioration revealed increasing breathlessness, not
relieved by her usual medication, forcing her to give up
her favourite walking routes. Past medical history
included stable asthma managed by her general practi-
tioner, recurrent urinary tract infection and osteoporosis.
She had no drug allergies and her prescribed medications
were: zopiclone 7.5 mg od; medroxyprogesterone acetate
5 mg od; conjugated oestrogens 0.3 mg od; amitriptyline
10 mg od; nitrofurantoin 100 mg tds; fluticasone 250 μg
inhaled od; naproxen 550 mg bd; hyoscine butylbromide
10 mg as required; paracetamol 1 gm as required up; and
salbutamol 200 μg inhaled as required. The dose of nitro-
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furantoin had been increased 5 months prior to admis-
sion from 100 mg od, she had been taking it for 6 months
prior to this dose increase. She had no risk factors for
development of liver pathology, did not smoke and rarely
drank alcohol.
On examination there were no signs of liver disease. Her
abdomen was soft with mild right upper quadrant tender-
ness. Respiratory examination was unremarkable with no
audible wheeze or crepitations, oxygen saturations were
97% at rest. The remaining examination did not reveal
any further signs and of note there was nothing to suggest
an underlying autoimmune disease.
A full blood count revealed a haemoglobin of 159 g/L
(normal 115–155) with no other abnormalities. Repeat
LFTs had deteriorated [see additional file 1] the remaining
biochemistry was normal. Chest radiograph demon-
strated bilateral interstitial and alveolar shadowing in the
middle and lower zones. Upper abdominal ultrasound
scan demonstrated an enlarged hypoechoic liver.
A high index of suspicion of an adverse drug reaction at
this point lead to cessation of nitrofurantoin. In addition
she was commenced on a course of oral corticosteroids;
Prednisone 40 mg od as an adjunct to cessation of the
nitrofurantoin.
A full screen for liver disease delivered the following
abnormal results; IgG was elevated at 15.0 g/L (normal
7.0–14.0). Anti-nuclear antibody was positive (diffuse,
chromosome positive pattern) at a titre of 1/80. Anti-
smooth muscle antibody was positive at a titre of 1/40.
Epstein Barr virus and Cytomegalovirus serology were
both consistent with past infection.
Pulmonary function tests demonstrated impaired diffu-
sion capacity of 0.70 mmol/min/kPa/L (49% predicted)
FEV1 2.64, FVC 3.30, FEV1/FVC 79.92%. High resolution
computer tomogram of the chest revealed peripheral alve-
olar shadowing and fibrotic changes [see Fig. 1]. A liver
biopsy was performed which showed moderate lobular
hepatitis characterised by zone 3 necrosis, which was con-
sidered to be consistent with a drug induced hepatitis.
After withdrawal of nitrofurantoin and commencement of
oral corticosteroids this woman made a good sympto-
matic recovery. At follow up LFTs had normalized [see
additional file 1] and diffusion capacity had increased to
0.83 mmol/min/kPa/L (58% predicted) her FEV1 was
2.97 and FVC 3.71 (FEV1/FVC 80.13%). Her chest radio-
graph was reported as normal at follow up. Her pred-
nisone was stopped after an 8 week course
Two years following her initial presentation and cessation
of nitrofurantoin she has had no recurrence of her symp-
toms.
Discussion
Nitrofurantoin is used for the prophylaxis and treatment
of uncomplicated urinary tract infection. Adverse drug
reactions (ADR) to nitrofurantoin include pulmonary
reactions, hepatic toxicity, blood dyscrasias and periph-
eral neuropathy [1]. Concomitant pulmonary and hepatic
toxicity secondary to nitrofurantoin is rare with few
reported cases [2-5].
We reviewed the possibility that her other medications
may have contributed to her combined pulmonary and
hepatic pathology. Of her prescribed medications, in
addition to nitrofurantoin, only medroxyprogesterone
had been reported as causing pulmonary fibrosis and this
only in combination with radiotherapy [6]. Drugs causing
combined lung and liver pathology are few and include
busulfan, chlorambucil, amiodarone, methotrexate as
well as nitrofurantoin [5]. With this information we felt
that nitrofurantoin was responsible. Additionally, the
findings of the liver biopsy were compatible with a drug
induced hepatitis adding weight to the diagnosis.
The vast majority of pulmonary reactions to nitrofuran-
toin (90%) are acute and characterised by fever, cough,
dyspnoea, and peripheral eosinophilia [1]. Radiological
findings include pulmonary infiltrates which resolve rap-
idly upon drug withdrawal [1]. Nitrofurantoin also causes
a range of chronic pulmonary disease, often presenting
with insidious onset of increasing dyspnoea, dry cough
and radiological evidence of fibrosis, as in this case [6,7].
Nitrofurantoin is also recognised to produce a picture of
High resolution computer tomogram of the chest showing  peripheral alveolar shadowing and fibrotic changes Figure 1
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hepatocellular toxicity consistent with chronic active hep-
atitis with elevated ANA, Anti Smooth Muscle antibodies
and elevated IgG [2]. Liver biopsy results in this patient
are similar to those seen in other reported cases of liver
and lung toxicity secondary to nitrofurantoin [4,5].
Initial treatment consists of drug withdrawal. In addition,
we elected to use oral corticosteroids, which previous
cases have also tried, despite no definite evidence to sup-
port their use in addition to withdrawal of nitrofurantoin
[5]. Interestingly this woman's symptoms did not
improve in response to the short course of prednisone
prescribed by her GP whilst still on nitrofurantoin. Ongo-
ing use of the drug would be a factor in refractoriness to
steroid treatment [8]. The underlying mechanism behind
nitrofurantoin toxicity remains uncertain; an immunolog-
ical response is suggested by the presence of autoantibod-
ies. Direct cytotoxic mechanisms; for example by
increased oxidative stress, have also been suggested [9].
Following drug withdrawal both acute and chronic reac-
tions to nitrofurantoin tend to resolve. Deaths have been
reported due to both chronic lung and liver damage
although these are rare [1]. Encouragingly even apparently
widespread fibrotic changes in the lungs have been seen to
resolve after nitrofurantoin withdrawal [10].
The use of nitrofurantoin for UTI prophylaxis in this
woman is clearly no longer appropriate. She vehemently
agreed with this and self initiated regular intake of dried
cranberries. There is some evidence to support her
approach [11]. In post-menopausal women topical intra-
vaginal estriol cream has been shown to be an effective
treatment for recurrent UTIs as lower post-menopausal
oestrogen levels cause vaginal flora changes predisposing
to infection [12].
An alternative to her previous prophylactic regime is self-
initiated intermittent treatment of UTIs with short course
antibiotics [12]. In light of her history this was our recom-
mendation to the patient; she found this an acceptable
management plan, as she was keen to minimize her intake
of further antibiotics.
Conclusion
Adverse drug reactions should be considered in patients
presenting with concomitant lung and liver toxicity with
the mainstay of treatment being drug withdrawal.
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Additional file 1
Serial liver function tests, before, at and after admission to hospital. This 
file shows a graphical representation of liver function tests throughout this 
patients' management.
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